Deka Bank Deutsche Girozentrale Enanta Pharmaceuticals Inc Transaction History

Deka Bank Deutsche Girozentrale

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 28, 2022	BUY	$56.06 - $74.11 $22,424 - $29,644	400 Added 11.27%	3,950 $273,000
Q4 2021 Feb 02, 2022	BUY	$60.19 - $97.37 $6,019 - $9,737	100 Added 2.9%	3,550 $264,000
Q3 2020 Oct 29, 2020	BUY	$43.36 - $53.53 $149,592 - $184,678	3,450 New	3,450 $152,000
Q4 2019 Feb 04, 2020	SELL	$57.95 - $66.61 $205,722 - $236,465	-3,550 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$60.08 - $88.17 $213,284 - $313,003	-3,550 Reduced 50.0%	3,550 $214,000
Q2 2019 Aug 01, 2019	BUY	$81.3 - $97.35 $219,510 - $262,845	2,700 Added 61.36%	7,100 $595,000
Q1 2019 May 10, 2019	BUY	$69.08 - $105.66 $58,718 - $89,811	850 Added 23.94%	4,400 $396,000
Q4 2018 Feb 12, 2019	SELL	$65.41 - $84.65 $55,598 - $71,952	-850 Reduced 19.32%	3,550 $253,000
Q3 2018 Nov 09, 2018	SELL	$85.46 - $126.37 $8,546 - $12,637	-100 Reduced 2.22%	4,400 $0
Q1 2018 May 03, 2018	SELL	$57.91 - $92.15 $5,791 - $9,215	-100 Reduced 2.17%	4,500 $358,000
Q3 2017 Nov 06, 2017	BUY	$37.91 - $46.8 $174,385 - $215,280	4,600	4,600 $183,000

110

21.1M

4.8K

4.6K

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $194M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.